# PharmaCyte Biotech, Inc.: Form 10-K for the period ended Apr 30, 2011

- Company: [PharmaCyte Biotech, Inc.](/companies/pmcb.md) (CIK 1157075)
- Form: 10-K
- Filed: 2011-08-15
- Accepted by EDGAR: Aug 15, 2011, 15:19 ET
- Period: 2011-04-30
- Accession: 0001262463-11-000129
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/1157075/000126246311000129/apvd2011nuvilex2011form10kv1.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1157075/000126246311000129/

## Business

As filed, 20,343 characters.

### Overview

Nuvilex, Inc. operates independently and through wholly-owned subsidiaries. We are dedicated to bringing to market scientifically derived products designed to improve the health and well-being of those who use them. The Company’s current strategy is to focus on developing and marketing products it believes have potential for long-term corporate growth.

### History of the Company

The Company was founded as DJH International, Inc., a Nevada corporation, on October 28, 1996, and changed its name to eFoodSafety.com, Inc. following the October 16, 2000 acquisition of Global Procurement Systems, Inc. The Company acquired Ozone Safe Food, Inc. for Common Stock on October 29, 2003. The Company’s early mission was to provide methods and products to ensure the safety of marketed fruits and vegetables worldwide. On February 4, 2004, the Company registered shares with the Securities and Exchange Commission and its Common Stock began publicly trading on the OTC Bulletin Board under the trading symbol EFSF. The Company did not issue shares of Common Stock pursuant to an initial public offering. With less than projected demand for its produce sterilization methods and software tracking products, the Company changed its strategy and acquired Knock-Out Technologies, Ltd. and MedElite, Inc. in May 2004 and August 2005, respectively, of which Knock-Out Technologies, Ltd. was a developer of products using organic, non-toxic, food based substances and MedElite, Inc. was the exclusive U.S. distributor of TalsynTM-CI Scar Cream (“Talsyn”), a topical scar- reducing cream. The Company’s new strategy was to bring to market scientifically derived products designed to improve the health and well-being of those who use them. The Company sold its Ozone Safe Food, Inc. operations in August 2005. In November 2006, the Company formed Cinnergen, Inc., a wholly-owned subsidiary, to manufacture and market a non-prescription liquid nutritional supplement designed to promote healthy glucose metabolism, and purEffect, Inc., another wholly-owned subsidiary, to manufacture and market purEffectTM, a four-step non-prescription acne treatment. On March 10, 2006, the Company licensed the marketing rights for purEffectTM to Charlston Kentrist 41 Direct, Inc. (“CK41”). In July 2007, the Company formed I-Boost, Inc., a wholly-owned subsidiary, to manufacture and market a food bar designed to improve the effectiveness of the human immune system. In March 2008, the Company formed Cinnechol, Inc., a wholly-owned subsidiary, to manufacture and market a non-prescription nutritional supplement designed to promote cardiovascular health. In February 2009, the Company sold the rights to the purEffectTM product to CK41 for an equity position in CK41 and future royalty compensation. In March 2009, the Company acquired Freedom2 Holdings, Inc., the manufacturer and marketer of Infinitink®, a permanent tattoo ink designed to be removed more easily using conventional laser removal methods. On March 18, 2009, the Company changed its name to Nuvilex, Inc.

### Current Business of the Company

Nuvilex manufactures, directly or indirectly through independent contractors, CinnergenTM, CinnecholTM, Infinitink® (and related private label ink products), and TalysnTM Scar Cream for sale worldwide.

Nuvilex markets its products both directly and through retail distribution partners. The Company’s retail distribution partners include The Vitamin Shoppe and other regional retail establishments.

The Company is also engaged in the research and development of OraphyteÔ, a non-toxic, biodegradable nematocide for use on turfgrass and crops as well as CitroxinÔ, a multi-use germicidal with anti-viral properties. Nuvilex has conducted its research and development activities through internal efforts, contract research organizations and university-based research.

### Going Concern

The Company's financial statements are prepared using accounting principles generally accepted in the United States of America (GAAP) applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. In addition, as of April 30, 2011, the Company had an accumulated deficit of $37,948,693, had incurred a net loss for the year ended April 30, 2011 of $1,397,716 and had negative working capital of $3,284,733 as a result of the parent company, Nuvilex, current assets of $104,747, and current liabilities of $3,389,479. Funding has been provided by Dr. Ryan and other investors which have primarily enabled continuance of Nuvilex to date. The Company’s current business plan requires additional funding beyond its anticipated cash flows from operations. These and other factors raise substantial doubt about the Company's ability to continue as a going concern.

### Strategy

With an overall goal of long-term growth, the Company is stabilizing its financial condition. Management believes its multi-part strategy will strengthen the Company’s position in both the long and short term. Nuvilex may seek to raise capital to fund growth opportunities and working capital needs. The Company’s financial stability efforts include three primary components:

1.

Reduction of the Company’ cash burn rate,

2.

The sale or lease of its Freedom-2 Holdings, Inc. property and implementation of the Company’s plan to resolve the amounts owed,

3.

Ongoing execution of the Company’s revenue growth strategy.

### Nuvilex Products (in alphabetical order)

### Cinnechol™

CinnecholÔ, a gluten free/wheat free all-natural nutritional supplement manufactured and sold by Cinnechol, Inc. (a wholly owned subsidiary of Nuvilex, Inc.). CinnecholÔ is designed to help maintain normal cholesterol levels and to support normal cardiovascular function. CinnecholÔ, along with a healthy diet and regular exercise, is intended to serve as a dietary supplement to help individuals manage numerous cardiovascular and metabolic disorders, including dyslipidemia, hypertension, hypoglycemia, and hyperglycemia. CinnecholÔ contains red yeast rice extract as well as a blend of other ingredients known to improve cardiovascular function (including niacin and gum guggul extract). CinnecholÔ may provide a natural alternative for those who have high cholesterol and are intolerant of, or elect not to take, drugs that are known as statins.

### Cinnergen™

CinnergenÔ, a gluten free/wheat free all-natural liquid whole food nutritional supplement that provides vital nutrients to help the body efficiently process glucose. CinnergenÔ contains 0 grams of carbohydrates and fats, has no calories, and does not contain any artificial flavors or sweeteners. CinnergenÔ helps to prevent conditions associated with pre-diabetes or diabetes types 1 and 2. CinnergenÔ delivers amino acids, vitamins, minerals, enzymes, antioxidants, and over a dozen all-natural chemicals derived from plants.

Research published in peer-reviewed medical journals suggests that some of the plant extracts in CinnergenÔ can help to control glucose levels in those who are pre-diabetic or individuals who suffer from type 1 or type 2 diabetes. In addition, studies suggest constituents of CinnergenÔ may help to reduce glucose absorption in the small intestine, limit synthesis of glucose by the liver and kidneys, and increase the body's glucose metabolism.

### Cinnsational™

Cinnsational™, a gluten free/wheat free all-natural calorie-free, liquid nutritional supplement that contains a concentrated blend of vitamins, essential amino acids, and other beneficial ingredients designed to help the body combat symptoms associated with alcohol sensitivity and alcohol-induced hangovers, including nausea, fatigue and headaches (formerly, Last Shot Hangover Remedy™).

### Citroxin™

CitroxinÔ is an all-natural, eco-friendly surface cleaner also referred to as Big 6 Plus. Independent laboratory testing of CitroxinÔ showed a 100% kill rate for the "big six" bacterial health threats, including E. coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, Streptococcus, and Black Mold. CitroxinÔ has also proven to be an effective antiviral composition against swine flu virus \[swine influenza virus (H1N1 subtype)\] and bird flu virus \[avian influenza viruses (H5N1, H9N1 and H9N9) viral subtypes\]. CitroxinÔ is protected by patents in the United States (U.S. 7,439,218) and worldwide (WIPO 2007/038265 A3).

**Cyclosurface3™** Cosmetics

Nuvilex’ patent-pending Cyclosurface3™ color enhancement technology brings the formulators and manufacturers of cosmetics and other consumer products the ability to use less wax and other aesthetically detrimental additives in their products. Cyclosurface3™ was developed by Freedom2, Inc., a wholly owned subsidiary of Nuvilex, Inc.

The technology is a lipophilic surface treatment used to improve the dispersion of pigments in aqueous and organic materials. Cyclosurface3™ technology helps formulators create products that feel lighter on the skin while making the skin look more radiant, all while maintaining or enhancing the color and durability of ancillary cosmetic product. Nuvilex has the potential to be the original equipment manufacturer (OEM) for Cyclosurface3™ technology cosmetic ingredients.

### I-Boost Immune Bar™

I-Boost Immune BarÔ, a gluten free/wheat free all-natural nutritional bar designed to protect, stimulate, and boost the immune system. The I-Boost Immune BarÔ delivers key nutrients that assist in maintaining, enhancing and stimulating the immune system and provides energy to keep going during a busy day. I-Boost bars contain a proprietary blend of vitamins, minerals, and other ingredients designed to enhance the body’s natural ability to defend itself. I-Boost Immune BarsÔ were originally designed in four flavors: Chocolate, Chocolate Mint, Peanut Butter and Oatmeal Cinnamon Raisin.

### Infinitink®

Infinitink®, a permanent yet removable tattoo ink, was engineered specifically for removal in fewer laser treatments than standard tattoo ink and is the result of advanced materials science research. InfinitinkÒ is made from ingredients generally recognized as safe (GRAS) by the U.S. Food and Drug Administration (FDA) for use in drugs and cosmetics. The technology used to create InfinitinkÒ is protected by U.S. patents 6,013,122, 6,800,122, 6,814,760, 6,881,249, 7,175,950, 7,285,364, 7,435,524 and European patent 1,107,724.

Typically, the lasers used for tattoo removal use wavelengths of 532 nm and 1064 nm. InfinitinkÒ tattoo pigments closely match these laser wavelengths. A clinical study confirmed InfinitinkÒ was more easily removed, with participants averaging ~90% tattoo removal.

### Oraphyte™

Oraphyte™, the Company’s all-natural nematocide, is a non-toxic, biodegradable proprietary formulation, created as a liquid or solid. The product works through a two-step process in which a nematode’s epidermis is damaged, compromising its immune system, and then is killed by the environment. Both formulations have been shown to significantly reduce nematode community density compared to the non-treated control. EPA sensitivity required testing has all been within normal limits, suggesting Oraphyte™ poses minimal risk to animals and humans. Oraphyte™ is protected by U.S. Patent 7,439,218.

Nuvilex believes Oraphyte™ will gain EPA approval for use in multiple arenas with a billion dollar market potential and is assessing the most valuable means for final development and marketing, ultimately with the aim of decreasing the need for chemical treatments presently available.

### purEffect™

purEffect™ is a 3 part, all-in-one acne treatment designed to cleanse, tone, and heal the skin and combines a unique blend of ingredients to help maintain a radiant, blemish-free complexion. Benzoyl peroxide, the active ingredient in purEffectÔ is the safest, most widely recommended ingredient used to treat acne, serving as an antibacterial compound, minimizing inflammation, and helping to prevent formation of new acne.

At present, this entire line of products has been advanced, undergone pre-marketing assessment and is gearing up for an expanded marketing presence by CK41 who acquired purEffectÔ from Nuvilex, yet is still connected to Nuvilex by virtue of the rights contract (described elsewhere herein).

### Specialty, Private Label Inks

The Company has the potential to manufacture specialty inks for private label customers. The specialty inks are derived from the Company’s Virgin™ and Infinitink™ product lines and are formulated to specific customer needs. The Company’s specialty inks are formulated to be all natural, heavy metal and toxin-free.

**TalsynÔ** Scar Cream

TalsynÔ Scar Cream is a unique, fragrant composition that delivers lipids, peptides, and botanical extracts to the skin and has been clinically proven to improve the appearance of keloids, surgical incisions, and scars. TalsynÔ Scar Cream accelerates healing and improves the appearance of scars through decreasing their width, length, depth, and redness for both old and new scars. The all-natural emollients in TalsynÔ help keep the skin looking healthy, vibrant, and well hydrated and its unique combination of rich, plant-derived ingredients will not damage clothing or stain fabrics. TalsynÔ Scar Cream is endorsed and used by leading plastic and reconstructive surgeons. At present, this product has been reinitiated by the Division of Natural Products and is gearing up for an expanded marketing availability including both physician availability and direct purchase for men, women and children.

### Marketing, Sales and Distribution

Nuvilex’s products are marketed, sold and distributed domestically and internationally directly by the Company and through third party marketing and distribution partners. These products can be purchased directly from Nuvilex using the Nuvilex website (www.nuvilex.com) or the subsidiary websites, such as Cinnergen (www.cinnergen.com). Whether or not third parties achieve market penetration is based on their commitment to invest in the marketing and sales of the various products. In part, the Division of Natural Product’s future success is dependent upon the efforts of its direct internet sales, resellers and third party distribution partners and their ability or inability to successfully market the Company’s products, any of which could adversely affect the business of the Company.

### Competition

There is intense competition among providers of nutritional supplements, aesthetic skin care treatments and cosmetics products, including tattoo inks. Many of these competitors have substantially greater financial and marketing resources than Nuvilex, stronger name recognition, brand loyalty and long-standing relationships with target customers. The Division of Natural Product’s future success continues to be dependent upon its ability to compete and its failure to do so could adversely affect its success.

### Government Regulations

The FDA ensures safety of the entire community through its regulations as disparate as biologics to drugs to some meats and dietary supplements, the latter of which fall under different regulations than "conventional" food and drug products. Under the Dietary Supplement Health and Education Act of 1994, the dietary supplement manufacturer is responsible for ensuring a dietary supplement is safe before it is marketed and the FDA is responsible after the products reach the market. Generally, domestic and foreign facilities that manufacture, process, pack, or hold foods for human or animal consumption in the United States are required to register their facility with the FDA, but supplement manufacturers do not need to register products nor get FDA approval before producing or selling dietary supplements. Nonetheless, manufacturers must make certain product label information is truthful and not misleading. FDA's post-marketing responsibilities include monitoring safety, including voluntary dietary supplement adverse event reporting and product information, labeling, claims, package inserts, and accompanying literature and the Federal Trade Commission regulates dietary supplement advertising.

The FDA also regulates cosmetics, although differently than other products they regulate. Cosmetic products and ingredients are not subject to FDA premarket approval authority, with the exception of color additives. However, the FDA may pursue enforcement action against violating products, or against firms or individuals who violate regulatory laws. Increased federal, state, local or international regulation over the Company’s products could adversely affect its business, financial condition and operations by requiring additional or new testing of products and imposing different or new licensing requirements. Therefore, Nuvilex has and continues to expend effort to ensure its products are safe and follow regulatory guidelines, requirements, and laws.

### Patents, Intellectual Property and Trade Secrets

Nuvilex considers intellectual property (IP) and patent protection to be of paramount important to its business. In addition, although the Company takes reasonable measures to protect its IP, the Company cannot guarantee it will be able to protect and enforce its IP or obtain international patent protection for its products as needed. Nuvilex and its subsidiaries own several trademarks and own or co-own 14 issued patents in three technical areas: pigment modification, microencapsulation, and disinfectant/germicidal compositions. Litigation may be required to enforce the Company’s products, IP rights, trade secrets, or determine the validity and scope of the proprietary rights of others and utilizing financial and operational resources, and the Company’s IP could be discovered to be owned by others, invalid, or unenforceable, potentially causing hardship on the Company.

### Freedom-2, Inc.

In the second quarter of 2009, the Company filed a provisional patent application on its Cyclosurface3™ technology. Cyclosurface3™ technology can be used to modify the surfaces of pigments (e.g., surface modification or surface functionalization) for cosmetic, personal care, and pharmaceutical applications, including, but not limited to, mascara, hair care products, tattoo inks, medical devices, and pharmaceutical excipients.

The microencapsulation technology used to create InfinitinkÒ, a registered trademark of Freedom-2, Inc, is protected by U.S. patents 6,013,122, 6,800,122, 6,814,760, 6,881,249, 7,175,950, 7,285,364, 7,435,524, worldwide patent WO/2006/019823 and European patent 1,107,724. Licensing has been previously provided to MT-Derm, based in Germany. Freedom-2, Inc. also has exclusive license to microencapsulation technology developed at Brown University (WO/2008/054874). There are presently outstanding patent applications in Japan.

### The Division of Natural Products: Research

Knock-Out Technologies, Ltd., a research group of The Division of Natural Products, created patents that engender the art of creating eco-friendly, biodegradable disinfectant and germicidal compositions encompassed by U.S. patent 7,439,218 and global patents U.S. WO/2007/038265 and WO/2009/089534. Furthermore, a provisional or utility patent application has been filed to protect the Oraphyte™ technology platform, an eco-friendly, biodegradable pesticide and insecticide used for agricultural applications, including turfgrass, from nematodes and protection of high-value crops from agricultural pests. Finally, a provisional patent application has been filed for CRS2™, an all-natural composition showing promise in treating tumor cell lines.

### Sources and Availability of Raw Materials

All of the raw materials, from their acquisition through their shelf life, have potential negative impact on the Company and or its subsidiaries and since all of our products contain ingredients that could at any time in the future be difficult to obtain in large quantities.

### Employees

Nuvilex, as of April 30, 2011, has eight employees. Nuvilex also utilizes consultants, independent contractors and temporary employees in finance and accounting, and other research, development and promotional capacities.

## Risk factors

As filed, 17,324 characters.

*You should carefully consider these factors that may affect future results, together with all of the other information included in this Form 10-K, in evaluating the business and the Company. The risks and uncertainties described below are those that the Company currently believes may materially affect its business and results of operations. Additional risks and uncertainties that Nuvilex is unaware of or that it currently deems immaterial also may become important factors that affect its business and result of operations. Nuvilex’ common shares involve a high degree of risk and should be purchased only by investors who can afford a loss of their entire investment. Prospective investors should carefully consider the following risk factors concerning the Company’s business before making an investment.*

*In addition, you should carefully consider these risks when you read “forward-looking” statements elsewhere in this Form 10-K. These are statements that relate to the Company’s expectations for future events and time periods. Generally, the words “anticipate,” “expect,” “intend,” and similar expressions identify forward-looking statements. Forward-looking statements involve risks and uncertainties, and future events and circumstances could differ significantly from those anticipated in the forward-looking statements.*

### Doubt Regarding Ability to Continue as a Going Concern

Nuvilex’s financial statements have been presented on the basis Nuvilex is and will remain a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company had minimal revenues and incurred net operating losses for the period October 1999 (inception) through April 30, 2011, and as such, the Company’s independent auditors have concluded these factors create an uncertainty about Nuvilex’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent, among other factors, on its continued success in marketing its products, containing costs, establishing a credit facility, and/or raising additional equity capital. The financial statements of Nuvilex do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

### Early Revenue Stage Company: Generation of Revenues

Nuvilex is an early revenue stage company and an investor cannot readily determine if the Company will become profitable. Nuvilex is likely to continue to experience financial difficulties during this early revenue stage and beyond. The Company may be unable to operate profitably, even if it generates additional revenues. Nuvilex may not obtain the necessary working capital to continue developing and marketing its products. Furthermore, the present products may not receive sufficient interest to generate revenues or achieve profitability.

8

### Need for Future Capital: Long-Term Viability of Company

Nuvilex will need additional capital to continue its operations.

There can be no assurance that the Company will generate revenues from present operations or obtain sufficient capital on acceptable terms, if at all. Failure to obtain such capital or generate such operating revenues would have an adverse impact on the Company’s financial position, operations and ability to continue as a going concern. Nuvilex’ operating and capital requirements during the next fiscal year and thereafter will vary based on a number of factors, including the level of sales and marketing activities for its services and products. There can be no assurance that additional private or public financing, including debt or equity financing, will be available as needed or if available, on terms favorable to the Company. Additionally, any future equity financing may be dilutive to stockholders present ownership levels and such additional equity securities may have rights, preferences, or privileges that are senior to those of Nuvilex’ existing common stock.

Furthermore, debt financing, if available, will require payment of interest and may involve restrictive covenants that could impose limitations on the flexibility of the Company to operate. Nuvilex’s failure to successfully obtain additional funding may jeopardize its ability to continue the business and its operations.

### Unpredictability of Future Revenues: Potential Fluctuations in Operating Results

As a result of Nuvilex’s limited operating history; the Company is currently unable to accurately forecast its revenues. Current and future expense levels are based largely on the Company’s marketing and development plans and estimates of future revenues. Sales and operating results generally depend on the volume and timing of orders and on the Company’s ability to fulfill such orders, both of which are difficult to forecast at this stage. Nuvilex may be unable to adjust spending in a timely manner to compensate for any unexpected revenue shortfall. Accordingly, any significant shortfall in revenues in relation to planned expenditures could have an immediate adverse effect on the Company’s business, prospects, financial condition and results of operations. Further, as a strategic response to changes in the competitive environment, Nuvilex may from time to time make certain pricing, service or marketing decisions that could have a material adverse effect on its business, prospects, financial condition and results of operations.

Nuvilex may experience significant fluctuations in future operating results due to a variety of factors, many of which are outside the Company’s control. Factors that may affect operating results include: (i) ability to obtain and retain customers, attract new customers at a steady rate and maintain customer satisfaction with products, (ii) the announcement or introduction of new services by Nuvilex or its competitors, (iii) price competition, (iv) the level of use and consumer acceptance of its products, (v) the amount and timing of operating costs and capital expenditures relating to expansion of the business, operations and infrastructure, (vi) governmental regulations, and (vii) general economic conditions.

### Flaws and Defects in Products

Products offered by Nuvilex may contain undetected flaws or defects when first introduced or as new versions are released. Any inaccuracy or defects may result in adverse product reviews and a loss or delay in market acceptance. There can be no assurance that flaws or defects will not be found in Nuvilex products. Flaws and defects, if found, could have a materially adverse effect upon the business operations and financial condition of the Company. Marketing of any of the Company’s potential products may expose the Company to liability claims resulting from the use of the Company’s products. These claims might be made by consumers, health care providers, sellers of the Company’s products or others. A claim, particularly resulting from a clinical trial, or a product recall could harm the Company’s business, results of operations, financial condition, cash flow and future prospects.

### Stock Price Volatility

The market price of the Company’s stock has fluctuated significantly in the past and may continue to fluctuate in the future. The Company believes such fluctuations will continue as a result of many factors, including US and World markets, financing plans, future announcements concerning the Company, the Company’s competitors or principal customers regarding financial results or expectations, industry supply or demand dynamics, new product introductions, governmental regulations, the commencement or results of litigation or changes in earnings estimates by analysts. In addition, in recent years the stock market has experienced significant price and volume fluctuations often for reasons outside the control of the particular companies. These fluctuations as well as general economic, political and market conditions may have an adverse affect on the market price of the Company’s common stock as well as the price of the Company’s outstanding convertible notes.

### Worldwide Economic Conditions

The Company’s financial performance depends significantly on worldwide economic conditions and the related impact on levels of consumer spending, which has recently deteriorated significantly in many countries and regions, including the U.S., and may remain depressed for the foreseeable future. Demand for the Company’s products is adversely affected by negative macroeconomic factors affecting consumer spending. The severe tightening of consumer credit, low level of consumer liquidity, and extreme volatility in credit and equity markets have weakened consumer confidence and decreased consumer spending. These and other economic factors have reduced demand for the Company’s products and harmed the Company’s business, financial condition and results of operations, and to the extent such economic conditions continue, they could cause further harm to the Company’s business, financial condition and results of operations.

### Dependence on Sales through Retailers and Distributors

The Company’s business depends significantly upon sales through retailers and distributors, and if the Company’s retailers and distributors are not successful, the Company could experience reduced sales, substantial product returns or increased price protection, any of which would negatively impact the Company’s business, financial condition and results of operations. A significant portion of the Company’s sales are made through retailers, either directly or through distributors. If the Company’s retailers and distributors are not successful, due to weak consumer retail demand caused by the current worldwide economic downturn, decline in consumer confidence, or other factors, the Company could continue to experience reduced sales as well as substantial product returns or price protection claims, which would harm the Company’s business, financial condition and results of operations.

### Limited Management Personnel

Under Nuvilex’s business plan, significant and material matters of business must be conducted and concluded in a timely fashion. The execution of the Company’s business plan is expected to place a significant strain on the Company’s management while providing little or no immediate compensation.

There can be no assurance that Nuvilex’s planned personnel, systems, procedures and controls will be adequate to support its future operations, that management will be able to hire, train, retain, motivate and manage personnel or that its management will be able to successfully identify, manage and exploit existing and potential market opportunities. If Nuvilex is unable to manage growth effectively, the Company’s business, prospects, financial condition, results and operations could be adversely affected.

### Competition

The market in which Nuvilex competes is highly competitive, and the Company has no assurance that it will be able to compete effectively, especially against established industry competitors with significantly greater financial resources. The Company expects to face competition from a few competitors with significantly greater financial resources, well-established brand names and large, existing customer bases. Nuvilex expects the level of competition to intensify in the future.

### Dependence on Management

Nuvilex’s performance will be substantially dependent on the continued services and on the performance of the current senior management and other key personnel of the Company. Nuvilex’s performance will also depend on the Company’s ability to retain and motivate its other officers and key employees. Nuvilex’s inability to retain its executive officers or other key employees could have a material adverse effect on the Company’s business, prospects, financial condition and results of operations. The Company’s future success will depend on its ability to identify, attract, hire, train, retain and motivate other highly skilled technical, managerial, merchandising, marketing and customer service personnel. Competition for such personnel is intense and there can be no assurance that Nuvilex will be able to successfully attract, assimilate and retain sufficiently qualified personnel. The failure to retain and attract the necessary technical and managerial personnel could have a material adverse effect on the Company’s business, prospects, financial condition and results of operations.

### Development of Brand Awareness

For certain market segments that Nuvilex plans to pursue, the development of its brand awareness is essential for it to reduce its marketing expenditures over time and realize greater benefits from marketing expenditures. If the Company’s brand-marketing efforts are unsuccessful, growth prospects, financial condition and results of operations would be adversely affected. Nuvilex’s brand awareness efforts have required, and will continue to require, incurrence of significant expenses.

### Intellectual Property Protection: Uncertainty of Protection of Proprietary Rights

Nuvilex currently relies on a combination of patents, trademarks, trade secret protection, non-disclosure agreements and licensing arrangements to establish and protect its proprietary rights. Despite efforts to safeguard and maintain Nuvilex’s proprietary rights, there can be no assurance that the Company will be successful in doing so or that its competitors will not independently develop products that are substantially equivalent or superior to Nuvilex’ products.

Nuvilex also relies on trade secrets and proprietary know-how, which the Company seeks to protect by confidentiality and non-disclosure agreements with its employees, consultants, and third parties. There can be no assurance that these agreements will not be breached, that the Company will have adequate remedies for any breach, or that certain of Nuvilex’s trade secrets and proprietary know-how will not otherwise become known or be discovered by competitors.

Protecting or defending the Company’s IP rights, to protect trade secrets, to determine the validity and scope of the proprietary rights of others, or to defend against claims of infringement or invalidity may require litigation. Such litigation, whether successful or unsuccessful, could result in substantial costs and diversions of management resources, either of which could have a materially adverse effect on Nuvilex’ business, prospects, financial condition, or operating results.

### Availability and Coverage of Insurance

For certain risks, the Company does not maintain insurance coverage because of cost and/or availability. Because the Company retains some portion of its insurable risks, and in some cases self-insures completely, unforeseen or catastrophic losses in excess of insured limits could have a material adverse effect on the Company’s financial condition and operating results.

### Federal, State, Local and Foreign Laws and Regulations

The Company is subject to laws and regulations enforced by the FDA, the DEA, the CDHS, foreign health authorities and other regulatory statutes including the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Food, Drug and Cosmetic Act, the Resource Conservation and Recovery Act, and other current and potential federal, state, local and foreign laws and regulations governing the use, manufacture, storage, handling and disposal of the Company’s products, materials used to develop the Company’s products, and resulting waste products. The Company’s past research, product development and manufacturing activities have involved the controlled use of hazardous materials and the Company may incur costs as a result of the need to comply with these laws and regulations.

### Penny Stock Regulation

The Company’s securities may be subject to “penny stock rules” that impose additional sales requirements on broker-dealers who sell such securities to persons other than established customers and accredited investors (generally those with assets in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together with their spouse). For transactions covered by these rules, the broker-dealer must make a special suitability determination for the purchase of such securities and have received the purchaser’s written consent to the transaction prior to the purchase. Additionally, for any transaction involving a penny stock, unless exempt, the “penny stock rules” require the delivery, prior to the transaction, of a disclosure schedule prescribed by the Securities and Exchange Commission relating to the penny stock market. The broker-dealer must also disclose the commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements must be sent disclosing recent price information on the limited market in penny stocks. Consequently, the “penny stock rules” may restrict the ability of broker-dealers to sell the Company’s securities. The foregoing required penny stock restrictions will not apply to the Company’s common stock if such securities maintain a market price of $5.00 or greater. The market price of the Company’s common stock may not reach or remain at such a level.

## Legal proceedings

As filed, 1,238 characters.

In July 2011 a claim was filed by Cornerstone Bank against Freedom-2, Inc., a wholly owned subsidiary of the Company, for amounts due under a promissory note. The bank is also seeking to foreclose its mortgage on the property located in Cherry Hill, New Jersey for which the promissory note is held. Although at this time it is unknown what any estimated loss may be, it is reasonable to assume at least a loss between $750,000 - $1,000,000 is possible, with a worst case scenario of a 100% liability plus any applicable fees. In addition, there is a claim to enforce a purported pledge of additional collateral of 14,605,614 shares of Nuvilex common stock as security for the Note. It should be noted that the shares pledged by Freedom-2 and purportedly owed by the Company to Cornerstone Bank were not part of the mortgage note, but the shares in question were above, beyond, and thus in addition to the note as collateral for obtaining the second mortgage modification so they have been indicated as additional collateral, since they were not part nor parcel of the original note nor its modification itself except as collateral. The Company has recorded a stock payable and expense in the amount of $730,281 to account for the shares.

## Management's discussion and analysis

As filed, 4,452 characters.

### SALES

Revenues from product sales for fiscal 2011 were $75,997 plus consulting revenues of $50,000 compared to $262,932 in fiscal 2010. Product sales in fiscal 2011 only occurred during the latter few months of the fiscal year, once new product liability insurance was acquired and manufacturing, sales and distribution were reinitiated. This was unlike fiscal 2010 which was replete with sales of multiple products throughout and was utilizing existing product liability insurance paid for in fiscal 2009.

### RESEARCH AND DEVELOPMENT

Research and development expenses for fiscal 2011 were $9,209 compared to $492,460 in fiscal 2010 and included those from Company efforts as well as external contract research organizations and University-based, Company-sponsored research activities. The Company’s research and development activities included, but were not limited to product conception, design, evaluation, formulation, manufacturing, packaging and testing. As with all corporate and university research, product conception, design and evaluation does not necessarily yield commercially viable products. It is the intention of the present management to fully utilize the prior year’s research efforts in advancing products not fully developed to date, particularly once present activities are actively moved forward.

Effort is now underway to utilize completed and incomplete research and formulate development plans based on such studies. This is typically one of the most challenging steps, but one management is truly committed to, i.e. that of monetizing research discoveries through multiple means, and is one presently being actively prepared and/or driven forward.

### SALES AND MARKETING

The Company incurred sales and marketing expenses of $10,830 in fiscal 2011 compared to $411,720 in fiscal 2010. The decrease in sales and marketing expenses was due in part to available cash resources to invest in such activities, and partly due to careful and logical utilization of scarce resources. Most of the available resources had been consumed during fiscal year 2010.

Presently, the Company regulates its sales and marketing expenses through its Internet-based Division of Sales and Marketing and its resellers and retail distributors.

### GENERAL AND ADMINISTRATIVE

General and administrative expenses were $227,816 in fiscal 2011, a decrease of $946,424 as compared to the $1,174,240 in expenses in fiscal 2010. These expenses pay for office and other overhead expenses. The Company took aggressive steps during the latter half of fiscal 2011 to reduce and maintain its general and administrative expenses at a low level including, but not limited to reductions in staffing and all other overhead expenses, including the receipt of stock as primary payment for executives.

### LOSS ON IMPAIRMENT OF ACQUIRED AND INTANGIBLE ASSETS

The Company recorded a $12,411 loss on disposal of fixed assets in fiscal year 2011. A $3,507,621 charge for impairment of goodwill, fixed assets and intangible assets was taken previously in fiscal 2010 associated with the acquisition of Freedom-2 Holdings, Inc.

### LIQUIDITY AND CAPITAL RESOURCES

As of April 30, 2011, the Company had negative working capital of $3,284,733. By adjusting the Company's operations to the level of capitalization, working with its creditors to establish a reasonable and timely manner for resolving outstanding debts and through small cash investments from new and existing shareholders, management believes it has sufficient resources to meet present cash flow needs. If the Company is not successful in generating sufficient liquidity from operations or in resolving its outstanding debt issues with its creditors on terms acceptable to the Company, this could have a materially adverse effect on the Company’s business, liquidity and financial condition. The Company’s independent certified public accountants have stated in their report, which is included as part of the Company’s audited financial statements for the fiscal years ended April 30, 2011 and 2010 that the Company has suffered recurring losses from operations which raises doubt about the Company’s ability to continue as a going concern.

The Company has no off-balance sheet arrangements, special purpose entities, financing partnerships or guarantees.

Management notes of the total liabilities of $3,389,479, the current Freedom-2 subsidiary’s liabilities are 89.3% of the liabilities or $3,025,400.

## Controls and procedures

As filed, 8,584 characters.

The Company’s upper Management, including the Chief Executive, Chief Financial, and Chief Operating Officers, as of the end of the period covered by this Annual Report on Form 10-K, have concluded our disclosure controls and procedures (as defined in Rules 13a-14(c) and 15d-14(c) under the Securities Exchange Act of 1934) were not effective, although efforts were made to do so, to ensure information required to be disclosed in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, but are aiming to become effective as we move forward.

Management, including the Chief Executive Officer and Chief Financial Officer, does not expect its disclosure controls and procedures or its internal controls will prevent all error or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance the objectives of the control system are met. Further, the design of a control system must reflect the fact that resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance all control issues and instances of fraud, if any, have been detected. To address the material weaknesses, management performed additional analysis and other post-closing procedures in an effort to ensure its consolidated financial statements included in this annual report have been prepared in accordance with generally accepted accounting principles and are as free of fraud as best as can be determined. Accordingly, management believes the financial statements included in this report fairly present in all material respects our financial condition, results of operations and cash flows for the periods presented.

**Changes in Internal Controls.**

There were no significant changes in our internal controls or other factors that could significantly affect these controls subsequent to the date of their evaluation. There were no significant deficiencies or material weaknesses recognized as of April 30, 2011, and therefore there were no corrective actions taken. However, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events and there is no certainty that any design will succeed in achieving its stated goal under all potential future considerations, regardless of how remote. It is management’s plan however, to work toward better assessment of any and all necessary internal controls and thereby to increase the capability to recognize errors and prevent fraud as the Company strives for bettering itself from this point. We have already initiated discussions to study, assess and create everything necessary throughout the remainder of the year to achieve effective disclosure controls and procedures. Nonetheless, this will remain a potential material weakness until such activities have been fully integrated.

**Management’s Report on Internal Control Over Financial Reporting.**

Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Securities Exchange Act, as amended. Internal control over financial reporting refers to a process designed by, or under the supervision of, our Chief Executive, Chief Financial and Chief Operating Officer, effected by our Board, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in connection with GAAP, including those policies and procedures that:

- pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;
- provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and
- provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our consolidated financial statements.

Because of its inherent limitations, internal control over financial reporting cannot provide absolute assurance of the prevention or detection of misstatements. In addition, projections of any evaluation of effectiveness to future periods are subject to risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In connection with the preparation of this Annual Report on Form 10-K for the year ended April 30, 2011, management, with the participation of our Chief Executive Officer, Chief Financial Officer, and Chief Operating Officer, has evaluated the effectiveness of our internal controls over financial reporting, pursuant to Rule 13a-15 under the Exchange Act. Management assessed the effectiveness of its internal control over financial reporting as of April 30, 2010 in order to determine the potential for or the existence of material weakness, defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. Our Chief Executive, Chief Financial, and Chief Operating Officer, have concluded the design and operation of our internal controls and procedures are not effective as of April 30, 2011. As a result, the following aspects of the Company were noted as potential material weaknesses:

1.

As of April 30, 2011, the Company’s control over financial reporting was not effective. Specifically, although a formally adopted and written code of business conduct and ethics that governs to the Company’s employees, officers and directors existed, it had not been disseminated nor specifically discussed to date, although discussions have been held which did specifically point out and discuss the critical nature of appropriate behavior, ethics and expectations as members of Nuvilex by the Chief Executive Officer with internal and external company members and specifically with each member of the Board of Directors, the Officers and the employees individually and as groups.

16

2.

Although they have communicated to their employees, Management has not fully developed its accounting policies and procedures. In addition, no Director of the Board of Directors qualifies as an Audit Committee Financial expert as defined in Item 407(d)(5)(ii) of Regulation S-B which may therefore, constitute a material weakness.

3.

As of April 30, 2011, the Company’s control over financial statement disclosure was not effective. Specifically, controls were not completely developed to guarantee all disclosures required would be fully addressed in our financial statements. Accordingly, management has determined its control deficiency constitutes a material weakness.

Because of these material weaknesses, Management has concluded the Company did not maintain effective internal control over financial reporting as of April 30, 2011, based on the criteria established in "Internal Control-Integrated Framework" issued by the COSO, criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework. It is the intention of the present Management to continue to study and establish COSO Control-Integrated Framework within Nuvilex during the coming year.

There were no significant changes previously in our internal controls over financial reporting that occurred during the fourth fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

This Annual Report on Form 10-K does not include an attestation report of the Company’s independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit us to provide only management’s report in this Annual Report on Form 10-K.

Filed Aug 15, 2011.
Source: SEC EDGAR, the filing index for accession 0001262463-11-000129. Last ingested by Listed: Nov 14, 2026, 20:52 ET. No prices; not investment advice.
